In vivo evidence of AD subtypes is supported by recent tau-PET studies that used flortaucipir to investigate tau distribution.39,40 The current study provides a backward engineering of foundational knowledge gained by examining the postmortem brain to be applied to antemortem neuroimaging modalities. This evidence concerns the gene MAPT and Alzheimer disease.